We read with great interest the recent Panorama article that discussed the rise in the Journal Impact Factor (JIF) of rheumatology journals and the potential effect of the coronavirus disease 19 (COVID-19) pandemic in this rise.1Although there has definitely been a rise in the JIF of journals following the COVID-19 pandemic, there are concerns about some aspects of the paper that we wish to discuss in this letter.2